S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Competitors

$14.02
+0.04 (+0.29%)
(As of 06/9/2023 ET)
Compare
Today's Range
$13.67
$14.10
50-Day Range
$13.28
$15.96
52-Week Range
$10.14
$22.76
Volume
627,585 shs
Average Volume
728,112 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.78

DCPH vs. VERV, AVDL, MNKD, KNSA, MRUS, MIRM, DAWN, OPK, CRNX, and CTIC

Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Verve Therapeutics (VERV), Avadel Pharmaceuticals (AVDL), MannKind (MNKD), Kiniksa Pharmaceuticals (KNSA), Merus (MRUS), Mirum Pharmaceuticals (MIRM), Day One Biopharmaceuticals (DAWN), OPKO Health (OPK), Crinetics Pharmaceuticals (CRNX), and CTI BioPharma (CTIC). These companies are all part of the "pharmaceutical preparations" industry.

Deciphera Pharmaceuticals vs.

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.

Deciphera Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Verve Therapeutics has a net margin of 0.00% compared to Deciphera Pharmaceuticals' net margin of -131.38%. Verve Therapeutics' return on equity of -37.63% beat Deciphera Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Deciphera Pharmaceuticals -131.38% -46.56% -36.58%
Verve Therapeutics N/A -37.63% -31.01%

In the previous week, Deciphera Pharmaceuticals and Deciphera Pharmaceuticals both had 5 articles in the media. Deciphera Pharmaceuticals' average media sentiment score of 0.72 beat Verve Therapeutics' score of 0.63 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Deciphera Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Verve Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

72.7% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Verve Therapeutics shares are held by institutional investors. 4.4% of Deciphera Pharmaceuticals shares are held by company insiders. Comparatively, 21.4% of Verve Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Deciphera Pharmaceuticals received 301 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 65.48% of users gave Deciphera Pharmaceuticals an outperform vote while only 41.38% of users gave Verve Therapeutics an outperform vote.

CompanyUnderperformOutperform
Deciphera PharmaceuticalsOutperform Votes
313
65.48%
Underperform Votes
165
34.52%
Verve TherapeuticsOutperform Votes
12
41.38%
Underperform Votes
17
58.62%

Verve Therapeutics has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deciphera Pharmaceuticals$134.04 million8.21-$178.93 million-$2.35-5.97
Verve Therapeutics$1.94 million548.66-$157.39 million-$3.14-5.47

Deciphera Pharmaceuticals currently has a consensus price target of $21.78, indicating a potential upside of 55.33%. Verve Therapeutics has a consensus price target of $38.63, indicating a potential upside of 124.69%. Given Verve Therapeutics' higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than Deciphera Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Deciphera Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Verve Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Verve Therapeutics beats Deciphera Pharmaceuticals on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DCPH vs. The Competition

MetricDeciphera PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.10B$6.02B$4.59B$6.28B
Dividend YieldN/A2.60%2.27%6.19%
P/E Ratio-5.9710.04127.6914.98
Price / Sales8.21401.923,401.6099.48
Price / CashN/A20.9592.48113.59
Price / Book2.784.814.705.30
Net Income-$178.93M$196.93M$118.08M$193.23M
7 Day Performance-0.43%0.46%0.89%1.52%
1 Month Performance0.72%0.95%1.52%5.17%
1 Year Performance17.62%17.72%8.61%3.11%

Deciphera Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERV
Verve Therapeutics
1.8505 of 5 stars
$17.95
+7.2%
$38.63
+115.2%
+17.3%$1.11B$1.94M-5.72113
AVDL
Avadel Pharmaceuticals
1.6938 of 5 stars
$14.84
+3.1%
$13.44
-9.5%
+489.5%$1.14B$22.33M-6.4066
MNKD
MannKind
1.7023 of 5 stars
$4.32
flat
$6.50
+50.5%
-13.6%$1.14B$99.77M-15.43348
KNSA
Kiniksa Pharmaceuticals
2.6016 of 5 stars
$15.19
+1.9%
$20.00
+31.7%
+75.2%$1.06B$220.18M5.48215
MRUS
Merus
2.1893 of 5 stars
$22.80
-0.3%
$42.78
+87.6%
+2.1%$1.06B$41.59M-6.85117
MIRM
Mirum Pharmaceuticals
2.2599 of 5 stars
$27.83
+3.3%
$49.00
+76.1%
+18.1%$1.06B$77.06M-7.62137Analyst Revision
DAWN
Day One Biopharmaceuticals
1.7177 of 5 stars
$14.37
+3.0%
$44.29
+208.2%
+87.7%$1.06BN/A-6.3055Analyst Revision
High Trading Volume
OPK
OPKO Health
2.2552 of 5 stars
$1.52
+4.8%
$4.13
+171.9%
-43.0%$1.17B$1.00B-4.004,196Analyst Upgrade
News Coverage
CRNX
Crinetics Pharmaceuticals
2.3324 of 5 stars
$22.01
+1.1%
$45.50
+106.7%
+10.4%$1.19B$4.74M-6.71143Insider Buying
News Coverage
Positive News
CTIC
CTI BioPharma
2.0462 of 5 stars
$9.05
flat
$10.29
+13.7%
+44.3%$1.19B$75.77M-15.6022

Related Companies and Tools

This page (NASDAQ:DCPH) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -